Successful Rituximab Monotherapy in Advanced-stage, Epstein-Barr Virus-positive Diffuse Large B-Cell Lymphoma in an Adolescent With Systemic Juvenile Idiopathic Arthritis. Issue 4 (May 2021)

• Record Type: Journal Article
• Authors: Takahashi, Takuto; Hobday, Patricia M.; Pozos, Tamara C.; Gordon, Peter M.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 43:Issue 4(2021)
• Publication Date: 2021-05
• Subjects: Epstein-Barr virus -- diffuse large B-cell lymphoma -- juvenile idiopathic arthritis -- immunosuppression -- rituximab; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001869
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL) in pediatrics most commonly occurs as an iatrogenic immunodeficiency-associated lymphoproliferative disease. We report an 18-year-old female individual with refractory systemic juvenile idiopathic arthritis, treated with multiple immunosuppressive agents, who was diagnosed with stage III, EBV+ DLBCL. The patient achieved sustained complete remission after 4 weekly doses of rituximab monotherapy and reduction of immunosuppression. This case suggests that a post-transplant lymphoproliferative disease-like treatment approach can be a safe and effective therapy in a nontransplant, yet severely immunosuppressed, patient with EBV+ DLBCL.